Our laboratory is currently recruiting postdoctoral fellows in immunology and medical oncology/hematology fellows.
Contact us for more information.
Research Aims
We aim to better understand lymphoma interactions with the normal immune system. Through integrating "omics" with functional immunologic assays, we hope to discover new immunotherapy targets and to better understand how to use currently available therapies.
Antigen Presentation
Through collaborations with experts across Stanford University, we have created an approach to profiling lymphomas that allows us to "see" lymphoma through the eyes of the immune system. By focusing on actively presented lymphoma antigens, we identified the lymphoma immunoglobulin as a critical source of cancer-specific antigens.
Major histocompatibility complex (MHC) class I and class II presentation of lymphoma immunoglobulin
Reference:
Khodadoust MS, Olsson N, Wagar LE, Haabeth OA, Chen B, Swaminathan K, Rawson K, Liu CL, Steiner D, Lund P, Rao S, Zhang L, Marceau C, Stehr H, Newman AM, Czerwinski DK, Carlton VE, Moorhead M, Faham M, Kohrt HE, Carette J, Green MR, Davis MM, Levy R, Elias JE, Alizadeh AA. Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens. Nature 543(7647): 723-727, 2017.
MHC presentation of B-cell lymphoma immunoglobulin variable regions
Reference:
Khodadoust MS, Olsson N, Chen B, Sworder B, Shree T, Liu CL, Zhang L, Czerwinski DK, Davis MM, Levy R, Elias JE, Alizadeh AA. B-cell lymphomas present immunoglobulin neoantigens. Blood 133(8): 878-881, 2019.
Predictive Markers for Lymphoma Immunotherapy
Immunotherapy can be an extremely effective treatment for some patients. Other patients may not benefit at all from the same therapy. We are profiling the lymphomas from patients receiving immunotherapy to better understand how one therapy can result in to two very different outcomes. We are discovering how lymphomas can evade the immune system, and which lymphoma features may be useful in selecting candidates for immunotherapies.
